Nuvectis Pharma, Inc. announced on June 29, 2026, that it is suspending its Sales Agreement with Leerink Partners LLC and reducing the total amount available for sales under the Sales Agreement Prospectus to $5 million. The company will not conduct any share sales under the current agreement unless a new registration statement or prospectus is filed. Nuvectis Pharma, Inc. is a pharmaceutical company focused on the development and commercialization of medicines for neurological and neurological-related disorders.
